Citations (51)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Ana Luiza L. Rocha, Rayana R. Campos, Marina M. S. Miranda, Laio B.P. Raspante, Márcia M. Carneiro, Carolina S. Vieira & Fernando M. Reis. (2017) Safety of hormonal contraception for obese women. Expert Opinion on Drug Safety 16:12, pages 1387-1393.
Read now
Read now
Andrea J Rapkin & Sharon A Winer. (2007) Drospirenone: a novel progestin. Expert Opinion on Pharmacotherapy 8:7, pages 989-999.
Read now
Read now
D. F. Archer. (2007) Drospirenone and estradiol: a new option for the postmenopausal woman. Climacteric 10:sup1, pages 3-10.
Read now
Read now
R. Sitruk-Ware. (2005) Pharmacology of different progestogens: the special case of drospirenone. Climacteric 8:sup3, pages 4-12.
Read now
Read now
Svetlana Vujović, Jasna Zidverc, Miloš Stojanović, Zorana Penezić, Miomira Ivović, Vladimir Đukić & Milka Drezgić. (2005) Drospirenone in the treatment of severe premenstrual cerebral edema in a woman with antiphospholipid syndrome, lateral sinus thrombosis, situs inversus and epileptic seizures. Gynecological Endocrinology 21:5, pages 243-247.
Read now
Read now
D. Apter, A. Borsos, W. Baumgärtner, G.-B. Melis, D. Vexiau-Robert, A. Colligs-Hakert, M. Palmer & S. Kelly. (2003) Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. The European Journal of Contraception & Reproductive Health Care 8:1, pages 37-51.
Read now
Read now
W. Oelkers. (2000) Author's reply. Gynecological Endocrinology 14:6, pages 477-478.
Read now
Read now
Articles from other publishers (44)
Ömer Özcan, Wendy P.J. den Elzen, Jacquelien J. Hillebrand, Martin den Heijer, Laura L. van Loendersloot, Johan Fischer, Henrike Hamer, Robert de Jonge & Annemieke C. Heijboer. (2024) The effect of hormonal contraceptive therapy on clinical laboratory parameters: a literature review. Clinical Chemistry and Laboratory Medicine (CCLM) 62:1, pages 18-40.
Crossref
Crossref
Pedro-Antonio Regidor, Anna Mueller & Manuela Mayr. (2023) Pharmacological and metabolic effects of drospirenone as a progestin-only pill compared to combined formulations with estrogen. Women's Health 19, pages 174550572211473.
Crossref
Crossref
Anna CAPOZZI, Giovanni SCAMBIA & Stefano LELLO. (2022) Clinical pharmacology of progestins. Minerva Obstetrics and Gynecology 74:4.
Crossref
Crossref
Kalinkina O.B., Tezikov Yu.V., Lipatov I.S. & Aravina O.R.. (2021) EFFICACY OF ACNE THERAPY IN PATIENTS WITH OVARIAN HYPERANDROGENISM. "Medical & pharmaceutical journal "Pulse", pages 35-42.
Crossref
Crossref
MELISSA F. KELLER, MICHELLE L. HARRISON & SOPHIE LALANDE. (2020) Impact of Menstrual Blood Loss and Oral Contraceptive Use on Oxygen-carrying Capacity. Medicine & Science in Sports & Exercise 52:6, pages 1414-1419.
Crossref
Crossref
S O Dubrovina. (2018) Topical issues in combined oral contraceptives usage. Gynecology 20:2, pages 60-63.
Crossref
Crossref
Gina C. Davis, Karen J. Gibson, David Casley & Mark A. Brown. (2017) Angiotensin II/Angiotensin (1–7) ratio and 24-h blood pressure throughout the menstrual cycle and in women using oral contraceptives. Journal of Hypertension 35:6, pages 1178-1186.
Crossref
Crossref
Fumitake Ito, Taisuke Mori, Osamu Takaoka, Yukiko Tanaka, Akemi Koshiba, Hiroshi Tatsumi, Koichi Iwasa & Jo Kitawaki. (2016) Effects of drospirenone on adhesion molecule expression and monocyte adherence in human endothelial cells. European Journal of Obstetrics & Gynecology and Reproductive Biology 201, pages 113-117.
Crossref
Crossref
Tercio Lemos de Morais, Cassiana Giribela, Marcelo Gil Nisenbaum, Grazia Guerra, Nilson Mello, Edmundo Baracat & Fernanda M. Consolim-Colombo. (2014) Effects of a contraceptive containing drospirenone and ethinylestradiol on blood pressure, metabolic profile and neurohumoral axis in hypertensive women at reproductive age. European Journal of Obstetrics & Gynecology and Reproductive Biology 182, pages 113-117.
Crossref
Crossref
Maria F Gallo, Laureen M Lopez, David A Grimes, Florence Carayon, Kenneth F Schulz & Frans M Helmerhorst. (2014) Combination contraceptives: effects on weight. Cochrane Database of Systematic Reviews 2014:1.
Crossref
Crossref
S.T. Bird, J.A.C. Delaney, M. Etminan, J.M. Brophy & A.G. Hartzema. (2013) Drospirenone and non-fatal venous thromboembolism: is there a risk difference by dosage of ethinyl-estradiol?. Journal of Thrombosis and Haemostasis 11:6, pages 1059-1068.
Crossref
Crossref
Ramzi Finan, Abeer Wasfi Annab, Salwa Abdalla, Farid Bedran, Mazen El-Zibdeh, Lina Shahen, Christoph Gerlinger, Erich Solomayer, Kubilay Ertan & Jan Endrikat. (2013) A drospirenone-containing oral contraceptive improved bleeding pattern and personal satisfaction in 914 women from Jordan, Lebanon and Syria. Health 05:07, pages 39-44.
Crossref
Crossref
Zoltán Lőcsei, Dóra Horváth, Károly Rácz, István Szabolcs, Gábor L. Kovács & Erzsébet Toldy. (2012) Progestin-dependent effect of oral contraceptives on plasma aldosterone/renin ratio. Clinical Biochemistry 45:16-17, pages 1516-1518.
Crossref
Crossref
Cassiana R.G. Giribela, Nilson R. Melo, Rita C.G. Silva, Valeria M. Hong, Grazia M. Guerra, Edmund C. Baracat & Fernanda M. Consolim-Colombo. (2012) A combined oral contraceptive containing drospirenone changes neither endothelial function nor hemodynamic parameters in healthy young women: a prospective clinical trial. Contraception 86:1, pages 35-41.
Crossref
Crossref
Maria F Gallo, Laureen M Lopez, David A Grimes, Kenneth F Schulz & Frans M Helmerhorst. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Regine Sitruk-Ware & Anita Nath. (2011) Metabolic effects of contraceptive steroids. Reviews in Endocrine and Metabolic Disorders 12:2, pages 63-75.
Crossref
Crossref
Rogério Bonassi Machado, Luciano de Melo Pompei, Arícia Galvão Giribela & Cassiana Galvão Giribela. (2011) Drospirenone/Ethinylestradiol: A Review on Efficacy and Noncontraceptive Benefits. Women's Health 7:1, pages 19-30.
Crossref
Crossref
Recep Yildizhan, Begum Yildizhan, Ertan Adali, Pinar Yoruk, Fatih Birol & Necdet Suer. (2009) Effects of two combined oral contraceptives containing ethinyl estradiol 30 μg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure. Archives of Gynecology and Obstetrics 280:2, pages 255-261.
Crossref
Crossref
Jan S. Endrikat, Nikola P. Milchev, Aleksandra Kapamadzija, Jadranka Georgievska, Christoph Gerlinger, Werner Schmidt & Sleem Feroze. (2009) Bleeding pattern, tolerance and patient satisfaction with a drospirenone-containing oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada. Contraception 79:6, pages 428-432.
Crossref
Crossref
Inka Wiegratz. 2009. Klinische Endokrinologie für Frauenärzte. Klinische Endokrinologie für Frauenärzte
249
301
.
Maria F Gallo, Laureen M Lopez, David A Grimes, Kenneth F Schulz & Frans M Helmerhorst. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Faustino R. Pérez-López. (2008) Clinical experiences with drospirenone: From reproductive to postmenopausal years. Maturitas 60:2, pages 78-91.
Crossref
Crossref
Andrea J RapkinMichelle McDonaldSharon A Winer. (2016) Ethinyl Estradiol/Drospirenone for the Treatment of the Emotional and Physical Symptoms of Premenstrual Dysphoric Disorder. Women's Health 3:4, pages 395-408.
Crossref
Crossref
Régine Sitruk-Ware, Geneviève Plu-Bureau, Joël Menard, Jacqueline Conard, Sushma Kumar, Jean-Christophe Thalabard, Barbara Tokay & Philippe Bouchard. (2007) Effects of Oral and Transvaginal Ethinyl Estradiol on Hemostatic Factors and Hepatic Proteins in a Randomized, Crossover Study. The Journal of Clinical Endocrinology & Metabolism 92:6, pages 2074-2079.
Crossref
Crossref
Régine L. Sitruk-Ware, Joël Menard, Mandana Rad, Jacobus Burggraaf, Marieke L. de Kam, Barbara A. Tokay, Irving Sivin & Cornelis Kluft. (2007) Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen. Contraception 75:6, pages 430-437.
Crossref
Crossref
David F. Archer. (2007) Drospirenone, a progestin with added value for hypertensive postmenopausal women. Menopause 14:3, pages 352-354.
Crossref
Crossref
Franca Fruzzetti, Stefano Lello, Veronica Lazzarini, Stefania Fratta, Marisa Orrù, Roberto Sorge, Luigi Minerba, Cabiria Ricci, Andrea Riccardo Genazzani, Gian Benedetto Melis & Anna Maria Paoletti. (2007) The oral contraceptive containing 30 μg of ethinylestradiol plus 3 mg of drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle: an observational study. Contraception 75:3, pages 199-203.
Crossref
Crossref
Martin Sillem. (2016) Yasminelle®: A New Low-Dose Combined Oral Contraceptive Containing Drospirenone. Women's Health 2:4, pages 551-559.
Crossref
Crossref
Cornelis Kluft, Jan Endrikat, Simone M. Mulder, Christoph Gerlinger & Renate Heithecker. (2006) A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 μg ethinyl estradiol and a reference containing desogestrel and 30 μg ethinyl estradiol. Contraception 73:4, pages 336-343.
Crossref
Crossref
Rogério Bonassi Machado, Fabrício Tachotti, Glauce Cavenague & Edna Maia. (2006) Effects of two different oral contraceptives on total body water: a randomized study. Contraception 73:4, pages 344-347.
Crossref
Crossref
Maria F Gallo, Laureen M Lopez, David A Grimes, Kenneth F Schulz & Frans M Helmerhorst. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
U. Winkler. 2005. Klinische Endokrinologie für Frauenärzte. Klinische Endokrinologie für Frauenärzte
221
257
.
Andrew M. Kaunitz. (2004) Enhancing oral contraceptive success: the potential of new formulations. American Journal of Obstetrics and Gynecology 190:4, pages S23-S29.
Crossref
Crossref
Maria F. Gallo, David A. Grimes, Kenneth F. Schulz & Frans M. Helmerhorst. (2004) Combination Estrogen–Progestin Contraceptives and Body Weight: Systematic Review of Randomized Controlled Trials. Obstetrics & Gynecology 103:2, pages 359-373.
Crossref
Crossref
Lothar A J Heinemann & J??rgen Dinger. (2004) Safety of a New Oral Contraceptive Containing Drospirenone. Drug Safety 27:13, pages 1001-1018.
Crossref
Crossref
Wichit Suthipongse & Surasak Taneepanichskul. (2004) An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 μg ethinylestradiol and 150 μg levonogestrel/30 μg ethinylestradiol in Thai women. Contraception 69:1, pages 23-26.
Crossref
Crossref
Ulrich Schwabe & Thomas Rabe. 2004. Arzneiverordnungs-Report 2003. Arzneiverordnungs-Report 2003
776
798
.
Walter Elger, Sybille Beier, Kunhard Pollow, Robert Garfield, Shao Qing Shi & Alexander Hillisch. (2003) Conception and pharmacodynamic profile of drospirenone. Steroids 68:10-13, pages 891-905.
Crossref
Crossref
Andrea Pettinato & S. Jean Emans. (2003) New contraceptive methods: update 2003. Current Opinion in Pediatrics 15:4, pages 362-369.
Crossref
Crossref
I. Wiegratz, E. Kutschera, J.H. Lee, C. Moore, U. Mellinger, U.H. Winkler & H. Kuhl. (2003) Effect of four oral contraceptives on thyroid hormones, adrenal and blood pressure parameters. Contraception 67:5, pages 361-366.
Crossref
Crossref
Sam Rowlands. (2003) Newer progestogens. Journal of Family Planning and Reproductive Health Care 29:1, pages 13-16.
Crossref
Crossref
Ulrich Schwabe & Thomas Rabe. 2003. Arzneiverordnungs-Report 2002. Arzneiverordnungs-Report 2002
704
725
.
Gretchen A. Casazza, Sang-Hoon Suh, Benjamin F. Miller, Franco M. Navazio & George A. Brooks. (2002) Effects of oral contraceptives on peak exercise capacity. Journal of Applied Physiology 93:5, pages 1698-1702.
Crossref
Crossref
Uwe Fricke & Ulrich Schwabe. 2001. Arzneiverordnungs-Report 2001. Arzneiverordnungs-Report 2001
23
71
.